Journal of Oncology

Use of Nanomedicines in the Treatment of Brain Tumors


Publishing date
01 Nov 2019
Status
Closed
Submission deadline
28 Jun 2019

Lead Editor
Guest Editors

1Division of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA

2Northwestern University, Chicago, USA

3Chinese Academy of Sciences, Beijing, China

This issue is now closed for submissions.
More articles will be published in the near future.

Use of Nanomedicines in the Treatment of Brain Tumors

This issue is now closed for submissions.
More articles will be published in the near future.

Description

Malignant brain tumors (e.g., glioblastoma) are some of the most fatal neoplasms with high heterogeneity and mortality. The blood-brain barrier (BBB) blocks the penetration of macromolecules (~100%) and small molecules (> 95%, e.g., antitumor drugs) to the brain. Additionally, brain tumors have unique development, progression, and metastasis features influenced by multidrug resistant pathways. The aggressive and invasive nature of brain tumors is a critical reason for diagnostic failure, leading to a low 5-year survival rate of 35%. Brain tumor patients frequently relapse in spite of conventional treatments such as radiotherapy, chemotherapy, immunotherapy, and surgery.

Nanomedicines to treat brain tumors can be prepared from polymeric materials such as poly(ethylenimine), poly(alkylcyanoacrylates), poly(amidoamine) dendrimers, poly(ε-caprolactone), poly(lactic-co-glycolic acid), polyesters (poly(lactic acid), polysaccharides (e.g., chitosan and alginate), amino acids (poly(lysine), poly(aspartic acid)), or proteins (e.g. gelatin and albumin) or from inorganic materials including gold, silicon dioxide, iron oxide, and quantum dots for imaging or synergistic therapy. Nanomedicine has taken many forms over the past decade to address various drawbacks in brain tumor treatment through novel designs. Liposomes, lipid nanoparticles, nanofibers, dendrimers, nanoemulsions, polymeric micelles, and inorganic nanoparticles are extensively exploited to cure brain tumors as nanoplatforms. The established surface-chemistry on the nanoparticles can allow for deep penetration in brain tumors. Nanocarriers can control the release rate of drugs for sustainable treatment with high cancer specificity. Nanoplatforms with multiple types of drugs have bypassed drug resistant pathways. However, there are many problems that should be addressed for practical use of nanomedicines in the treatment of brain tumors. Although drugs based on nanoplatforms can penetrate the tumor up to several millimeters, they are still unsuitable for reaching deeper regions of the human brain. Also, drugs might accidentally be released prematurely from their parent nanoplatforms before reaching the brain tumor site, resulting in toxicity to normal cells.

We welcome the submission of original research as well as review articles that address specific targeting, bypassing multidrug resistance and the BBB, and deeper penetration of nanomedicines in the field of brain tumor treatment.

Potential topics include but are not limited to the following:

  • Nanomedicines to specifically target brain tumor
  • Research on nanomedicines that can overcome the brain-blood barrier (BBB)
  • Research on nanomedicines that can overcome multidrug resistance
  • Sustained release of nanomedicine in brain tumors
  • Nanomedicines to target brain tumors with deep penetration
Journal of Oncology
 Journal metrics
Acceptance rate24%
Submission to final decision66 days
Acceptance to publication37 days
CiteScore1.400
Impact Factor2.206
 Submit

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.